Blueprint Medicines Corporation
BPMC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $5 | $6 | $3 | $6 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $1 | $0 | $0 |
| Enterprise Value | $6 | $6 | $3 | $6 |
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | 104% | 22.2% | 13.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 96% | 94.9% | 91.3% | 90% |
| EBITDA | $0 | -$0 | -$1 | -$1 |
| % Margin | 3.8% | -188.6% | -252.6% | -348.9% |
| Net Income | -$0 | -$1 | -$1 | -$1 |
| % Margin | -13.2% | -203.3% | -273.2% | -357.7% |
| EPS Diluted | -1.07 | -8.37 | -9.35 | -11.01 |
| % Growth | 87.2% | 10.5% | 15.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$1 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$1 | -$1 |